Takeda Pharmaceutical Company Limited
TKPHF
$26.44
-$1.28-4.63%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.52% | 10.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.52% | 10.85% | |||
| Cost of Revenue | -3.24% | 8.74% | |||
| Gross Profit | -0.61% | 12.01% | |||
| SG&A Expenses | -2.96% | -8.73% | |||
| Depreciation & Amortization | -0.49% | -0.04% | |||
| Other Operating Expenses | 161.82% | 106.97% | |||
| Total Operating Expenses | 0.37% | 4.32% | |||
| Operating Income | -10.81% | 60.28% | |||
| Income Before Tax | -81.68% | 248.13% | |||
| Income Tax Expenses | 48.31% | 761.85% | |||
| Earnings from Continuing Operations | -109.24% | 227.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -95.83% | 33.34% | |||
| Net Income | -109.30% | 227.09% | |||
| EBIT | -10.81% | 60.28% | |||
| EBITDA | -5.61% | 75.37% | |||
| EPS Basic | -109.22% | 228.46% | |||
| Normalized Basic EPS | -18.19% | 62.93% | |||
| EPS Diluted | -109.36% | 226.54% | |||
| Normalized Diluted EPS | -16.95% | 60.50% | |||
| Average Basic Shares Outstanding | 0.81% | -1.07% | |||
| Average Diluted Shares Outstanding | -0.67% | 0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -1.64% | 13.39% | |||